LexDanaLexDanabeta
Inventor

Antonin de Fougerolles

Inventor
Waterloo, BE

Overview

99→
Patents
2002–2020
Patent span
Chemistry
Primary field (CPC C)

Patents· 99 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary
C12NMicroorganisms or enzymes20%
A61KPreparations for medical, dental or toiletry purposes19%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations17%
C07KPeptides14%
C12YEnzymes11%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture8%
C07HSugars6%
Y02ATechnologies for adaptation to climate change4%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests0%
C07DHeterocyclic compounds0%
PatentTitleYear
10,772,975Modified Polynucleotides for the production of biologics and proteins associated with human disease202010,703,789Modified polynucleotides for the production of secreted proteins202010,583,203In vivo production of proteins202010,577,403Modified polynucleotides for the production of secreted proteins202010,550,391Organic compositions to treat beta-ENaC-related diseases202010,501,512Modified polynucleotides201910,501,513Modified polynucleotides for the production of oncology-related proteins and peptides201910,493,167In vivo production of proteins201910,472,628Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene201910,463,751Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins201910,385,106Modified polynucleotides for the production of secreted proteins201910,286,086Alternative nucleic acid molecules and uses thereof201910,258,698Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions201910,155,029Terminally modified RNA201810,081,811Organic compositions to treat Beta-ENaC-related diseases20189,950,068Delivery and formulation of engineered nucleic acids20189,868,950'Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene'20189,827,332Modified polynucleotides for the production of proteins20179,828,416Modified polynucleotides for the production of secreted proteins20179,814,760'Modified polynucleotides for the production of biologics and proteins associated with human disease'20179,790,531'Enzymes and polymerases for the synthesis of RNA'20179,782,462'Modified polynucleotides for the production of proteins associated with human disease'20179,752,152'Organic compositions to treat beta-ENaC-related diseases'20179,675,668'Modified polynucleotides encoding hepatitis A virus cellular receptor 2'20179,597,380'Terminally modified RNA'20179,587,003'Modified polynucleotides for the production of oncology-related proteins and peptides'20179,572,897'Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins'20179,572,896'In vivo production of proteins'20179,533,047'Delivery and formulation of engineered nucleic acids'20179,512,456'Enzymes and polymerases for the synthesis of RNA'20169,504,734'Modified polynucleotides for the production of nuclear proteins'20169,428,535'Modified nucleosides, nucleotides, and nucleic acids, and uses thereof'20169,376,683'Organic compositions to treat beta-ENaC-related diseases'20169,303,079'Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins'20169,301,993'Modified polynucleotides encoding apoptosis inducing factor 1'20169,295,689'Formulation and delivery of PLGA microspheres'20169,283,287'Modified polynucleotides for the production of nuclear proteins'20169,271,996'Formulation and delivery of PLGA microspheres'20169,254,311'Modified polynucleotides for the production of proteins'20169,255,129'Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1'20169,233,141'Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders'20169,220,755'Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders'20159,220,792'Modified polynucleotides encoding aquaporin-5'20159,221,891'In vivo production of proteins'20159,216,205'Modified polynucleotides encoding granulysin'20159,206,421'Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene'20159,192,651'Modified polynucleotides for the production of secreted proteins'20159,186,372'Split dose administration'20159,187,516'Compositions and methods for inhibiting expression of a gene from the Ebola virus'20159,149,506'Modified polynucleotides encoding septin-4'20159,114,113'Modified polynucleotides encoding citeD4'20159,107,886'Modified polynucleotides encoding basic helix-loop-helix family member E41'20159,096,665'Antibodies against monocyte chemotactic proteins'20159,095,552'Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1'20159,089,604'Modified polynucleotides for treating galactosylceramidase protein deficiency'20159,080,175'Organic compositions to treat Beta-ENaC-related diseases'20159,062,310'Compositions and methods for inhibiting expression of factor VII gene'20159,061,059'Modified polynucleotides for treating protein deficiency'20159,050,297'Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator'20159,029,338'Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus'20158,999,380'Modified polynucleotides for the production of biologics and proteins associated with human disease'20159,000,143'Compositions and methods for inhibiting expression of IKK-B gene'20158,980,864'Compositions and methods of altering cholesterol levels'20158,912,316'Compositions and methods for inhibiting expression of CD45 gene'20148,754,062'DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides'20148,735,369'Compositions and methods for inhibiting expression of a gene from the Ebola virus'20148,710,200'Engineered nucleic acids encoding a modified erythropoietin and their expression'20148,680,069'Modified polynucleotides for the production of G-CSF'20148,664,193'Compositions and methods for inhibiting expression of factor VII gene'20148,664,194'Method for producing a protein of interest in a primate'20148,598,335'Organic compositions to treat Beta-ENaC-related diseases'20138,557,240'Method for the treatment of inflammatory disorders'20138,546,554'Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene'20138,519,112'Humanized antibodies against monocyte chemotactic proteins'20138,431,125'Methods of treating lupus nephritis using antibodies against monocyte chemotactic proteins'20138,354,390'Compositions and methods for inhibiting expression of a gene from the ebola virus'20138,344,130'Organic compositions to treat Beta-ENaC-related diseases'20138,344,129'Organic compositions to treat Beta-ENaC-related diseases'20138,344,127'Organic compositions to treat beta-ENaC-related diseases'20138,344,131'Organic compositions to treat beta-ENaC-related diseases'20138,334,273'Compositions and methods for inhibiting expression of factor VII gene'20128,293,719'iRNA agents targeting VEGF'20128,288,525'Compositions and methods for inhibiting expression of CD45 gene'20128,227,188'Enhancement of influenza gene expression'20128,084,031'Method for the treatment of inflammatory disorders'20118,003,619'Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide'20117,973,020'Compositions and methods for inhibiting expression of a gene from the ebola virus'20117,972,597'Methods of reducing chemotaxis using antibodies against monocyte chemotactic proteins'20117,968,680'Polynucleotides encoding members of the human B lymphocyte activation antigen B7 family and polypeptides encoded thereby'20117,947,659'iRNA agents targeting VEGF'20117,919,473'IRNA agents targeting VEGF'20117,888,498'Compositions and methods for inhibiting expression of IKK-B gene'20117,888,479'Humanized antibodies against monocyte chemotactric proteins'20117,871,985'Compositions and methods for inhibiting expression of factor VII gene'20117,759,320'Compositions and methods for inhibiting expression of a gene from the Ebola'20107,737,265'RNAi modulation of HIF-1 and therapeutic uses thereof'20107,632,501'Antibodies against monocyte chemotactic proteins'20097,405,277'Antibodies against monocyte chemotactic proteins'20086,429,303'Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same'2002

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2002–2019Based in Brookline, MA, US· patent location history
2008–2015Patents assigned to BIOGEN IDEC INC (10)· patent assignee history
2010–2019Patents assigned to ALNYLAM PHARMACEUTICALS INC (24)· patent assignee history
2011–2015Patents assigned to DE FOUGEROLLES ANTONIN (18)· patent assignee history
2011–2020Based in Cambridge, MA, US· patent location history
2014–2017Patents assigned to MODERNA THERAPEUTICS INC (35)· patent assignee history
2015–2020Based in Waterloo, BE· patent location history
2016–2020Patents assigned to MODERNATX INC (25)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
MODERNA THERAPEUTICS INC352014–2017
MODERNATX INC252016–2020
ALNYLAM PHARMACEUTICALS INC242010–2019
DE FOUGEROLLES ANTONINself182011–2015
BIOGEN IDEC INC102008–2015
Locations
LocationPatentsSpan
Waterloo, BE462015–2020
Brookline, Massachusetts, US392002–2019
Cambridge, Massachusetts, US142011–2020